Howard Chang, senior author of the study and an associate Prof. of dermatology, Stanford Caner Center explained that dysregulation of a lately identified form of RNA, HOTAIR occurs in breast cancer leading to it driving the tumour cells into metastasis and worsening likelihood of recovery in such women.

Chang along with his associates have been researching HOTAIR (HOX antisense intergenic RNA) for many years, endeavouring to comprehend the reason why RNA molecules which are not transformed into proteins are that common and any other aspects they could be carrying out. Chang stated that there are over ten thousand huge interceding non-coding RNA (also known as lincRNA) in the human genome which signifies a novel group of genes which do not build protein, however they are capable of affecting gene expression in an unknown manner.

In a 2007 conducted study, researchers cited that HOTAIR dons a significant part in assisting cells recognize their position in the body and what they are believed to turn into. It functions by triggering a set of enzymes known as PRC2 (Polycomb Repressive Complex 2) entailed in DNA binding. The study finding was the foremost to illustrate that lincRNA could have an impact on the manner in which remote genes located on other chromosomes expressed and offers a hint of their comprehensive significance in the body.

During the present study, researchers contrasted HOTAIR levels expressed in normal breast tissues of humans with those of primary breast cancer tumor types and those which had spread to other areas of the body. They uncovered that nearly 1 or every 3 primary tumors had HOTAIR expression levels which were more than a hundred folds higher in comparison to that of normal breast tissues. HOTAIR expression was a hundred or thousand folds more in metastatic tumors.

Investigators then replicated the testing employing samples from over a hundred breast cancer cases that had well-documented consequent medical pasts. They uncovered that in females that had elevated HOTAIR expression levels in their primary tumors had nearly three folds greater likelihood as compared to other women in that set to have tumor spreading and facing fatality in the next fifteen years. The link appeared to be strong irrespective of the size of tumor, staging or HR status.

Researchers then observed that when HOTAIR expression was blocked in an atypical cell line which exercised greater levels impeded its capability of accomplishing metastasis. They also illustrated that cells which lack PRC2 expression failed in responding in the analogous manner to HOTAIR expression. Cells observed to have HOTAIR over-expression exhibited modified PRC2 binding patterns and variations in levels of expression of over eight hundred genes which are offenders in breast cancer advancing.

Chang states that the upshots which such lincRNAs could have on cancer advancing are more intricate than was earlier perceived. He further explained that they could be employed as biomarkers; however, they might additionally be an important part in treatment of severe breast cancer type.

Investigators deem that in case HOTAIR expression in tumor cells could be blocked then it could be an important line of attack for inhibiting metastasis and improving likelihood of recovering in patients with severe breast cancer type.

The forty-one-year old Minogue would be peeling off and donning zilch except for a dazzling smile and silken piece of fabric bearing Fashion Targets Breast Cancer emblem over it in an eye-catching picture captured by famous snapper Mario Testino.

Kylie’s association in the breast cancer awareness campaign has come almost 5 years subsequent to her diagnosis of breast cancer during May 2005. Subsequent to have undergone a year’s treatment course that entailed partial mastectomy for removal of a malignant tumor, chemotherapy and radiotherapy 8 months anon, the pop diva eventually did manage to achieve remission in 2006. Minogue was then able to restart her ‘Showgirl’ tour in the later part of 2006.

Minogue spoke passionately about how the breast cancer awareness campaign meant a lot to her and was for a cause very close to her heart. She mentioned about her unequivocal support to their endeavours in fund-raising for the crucial effort taken on by Breakthrough Breast Cancer.

Revving up the glam quotient were actress Sienna Miller and expectant mother, supermodel Claudia Schiffer who joined Kylie in the eye-catching novel campaign.

These fresh pictures concur with the unveiling of the novel Target campaign that is raising funds for Breakthrough Breast Cancer in alliance with numerous retail stores.

Since its inception in 1996, the Target campaign has till date been able to amass over ten million pounds towards the charity.

Direct 30% earnings from auction of items for the campaign would be going straight to Breakthrough Breast Cancer.

In the light of this latest revelation, how would it translate for individuals undergoing cancer treatment and what would it mean for those apprehensive regarding their risk of developing cancer.

Explained below are answers to several of the commonly posed queries regarding aspirin and breast cancer.

Is breast cancer survival truly improved due to aspirin intake?

Solely a clinical study wherein an arbitrarily allocated treatment is analysed against a dormant placebo could help in proving whether a treatment is actually effectual.

Till such evidence is obtainable, the subsequent ideal thing is a trial wherein individuals undergoing the treatment are inspected over a span of time. The Nurses Health trial did a follow-up on over four thousand nurses that had undergone breast cancer treatment at least a year back.

The findings of this study showed that those nurses who had taken aspirin had a drastically lesser likelihood of breast cancer related death and of cancer recurring at another location. Following adjustment for cancer staging, status of menopause, body mass and hormonal sensitiveness of the tumor, women that had taken aspirin on all days of the week had a forty-three percent lesser likelihood of death due to breast cancer.

These outcomes could be applicable to solely those women that had survived a minimum of 4 years subsequent to having undergone treatment for breast cancer. However, as ninety percent of the women detected with having breast cancer had a minimum of 5 year survival rate, hence investigators of this study consider that their findings hold substantial clinical significance.

Could aspirin be used as an alternative to other treatments for breast cancer?

Aspirin cannot be used in place of other existent breast cancer treatments. In case aspirin really aids in averting breast cancer from recurring, it would do so solely when merged with suggested cancer treatments.

Could aspirin avert breast cancer?

A number of researches indicate that aspirin could reduce risk of breast cancer developing among women that did not have the ailment. Other trials have reached the contrary outcome.

On combining data obtained from numerous trials, there is an indication that aspirin or other NSAID (non-steroidal anti-inflammatory) medications like ibuprofen could cause slight reduction in breast cancer risk.

Majority of the women do not get breast cancer. Daily intake of aspirin for protracted periods of time has its own risks inclusive of chances of developing gastrointestinal bleeding. This would translate to the fact that in majority of the women the risks of aspirin intake could well be exceeding the advantages of averting breast cancer.

But, aspirin when taken following doctor’s advice and directions, regular less-dosage aspirin usage is believed to curtail risk of cardiovascular ailment. It is still unclear if women belonging to the higher risk bracket for developing breast cancer could be able to garner any additional advantages from aspirin intake.

CS is believed to be rare, though it is possibly under-detected. It is approximated that CS affects 1 in every two lakh people.

CS is typified by increased chances of developing both non-cancerous and cancerous tumors inflicting breast, thyroid and endometrial lining of the uterus.

Cowden syndrome symptoms

Key signs and symptoms of CS are explicated below:

• Trichilemmomas – skin tags.
• Papillomatous papules.
• Macrocephaly – more than average head circumference or enlarged head.
• Breast fibrocystic disease – A condition typified by existence of malignant breast tissues.
• Greater risk of developing breast cancer, thyroid cancer, kidney cancer, meningoima or endometrial cancer.
• Mentally retarded.
• Tiny bumpy appearance on the facial area.
• Non-malignant brain tumor – Lhermitte Duclos disease.
• Non-malignant thyroid variations – Goiters – An enlarged thyroid gland.
• Hamartomas.
• GI tract Polyposis.
• Lumps noted in mucous membrane, intestinal tract or skin.
• Café au lait spots – pigmented skin lesions that could range from lighter shades to deep browns because of excessive melanosomes in malpighian cells instead of excessive melanocytes.
• Hypopigmentation – Skin loses pigment and turns whiter (paler).
• Lipoma – non-cancerous fatty tumors.
• Fibroma – non-cancerous fibrous tumors.
• Uterine fibroids.

Cowden Syndrome Diagnosis

CS is identified in case an individual has 2 or more major characteristics of either macrocephaly, breast cancer, thyroid cancer, endometrial cancer and 4 or above of the remaining features, or 1 major trait and 1 minor trait.

A blood test could ascertain whether a person is having an alteration or mutation in the PTEN gene which is indicative of CS presence.

Cowden Syndrome Causes

CS is a heritable condition wherein chances of developing cancer and other traits could be passed through generations in a kin. Alterations in the PTEN gene are believed to be causing CS.

Screening choices for CS

Wide-ranging screening choices comprise of:

• Annual physical exam starting at eighteen years of age, or 5-10 years younger than what the earliest cancer identification was found in the kin.
• Annual exam by a skin specialist.
• Annual urine sample analysis.
• Baseline colonoscopy once reaching fifty years of age.

Screening Options for Females

• Breast self-exams to be conducted every month once turned eighteen years of age.
• Annual clinical breast exam starting from twenty-five years of age or 5-10 years below what the foremost breast cancer identification was spotted in the kin.
• Annual mammography and MRI (Magnetic resonance imaging) of the breasts commencing at ages of thirty to thirty-five years or 5-10years below what age the earliest breast cancer detection was in the kin.
• Annual biopsy conducted of endometrial or uterus starting at thirty-five to forty years, or 5-10 years below what was the foremost endometrial cancer identification in the kin.
• Annual trans-vaginal ultrasound scans to be conducted among women in their post-menopausal phase.

Screening choices for Males

• Doing a breast self-exam every month.

The multi-gene test known as Oncotype DX manufactured by Genomic Health Industries lead to doctors changing their treatment suggestions in about thirty-two percent of the cases whereas twenty-seven percent of the patients modified their treatment choices. In majority of these cases, the amendment in decision was observed from both the doctors as well as the patient’s end to steer clear from undergoing chemotherapy.

The Oncotype DX multi-gene test evaluates twenty-one genes from a neoplasm sample for ascertaining how progressive the neoplasms were. An analysis score lying from zero to one hundred forecasted the probability of cancer recurring. In case of those women having low test scoring, chemotherapy treatment was not suggested.

The Multi-gene test was firstly made accessible during 2004 and since then above one lakh, twenty thousand women with breast cancer have taken this test. The test is designed for those individuals that are having a breast cancer type, known as estrogen receptor-positive which has not metastasized to the lymph nodes. Nearly one lakh of these cases are identified on a yearly basis.

The study performed had eighty-nine entrants with breast cancer that had undergone the multi-gene test and were treated by seventeen oncologists. The treatment verdicts in case of twenty-eight patients were altered by doctors. Among twenty of such cases, the treatment decision was altered from HRT (hormone replacement therapy) along with chemotherapy to solely HRT. 24 of the patients altered their treatment choices inclusive of 9 patients that chose to drop chemotherapy.

This is the foremost study which shows that outcomes of the multi-gene test concurrently impacted verdicts by doctors and among patients analogously. The physicians stated that the multi-gene test helped in augmenting their assurance in the treatments they recommended in nearly seventy-six percent of the cases. In ninety-seven percent of the cases, physicians stated that they would suggest undergoing the test once more.

On obtaining their test outcomes, patients cited that they felt considerably lesser extent of conflict regarding their choices and thus sensed appreciably lesser levels of anxiousness regarding their state of affairs.

The multi-gene test is obtainable at about four thousand dollars, usually covered in insurance and has positively impacted breast cancer treatment. Scientists state that the test could by and large reduce costs by evading the outlay of chemotherapy in a number of patients.

When the outcome of mammography gives dubious findings, doctors mostly employ ultrasound to attain added information. On the other hand ultrasound has the possibility to lead to additional biopsies due to its comparatively squat specificity or incapability to precisely differentiate cancerous lesions from benign lesions. According to the American Cancer Society about eighty percent of breast lesions that underwent biopsies turned out to be benign in nature.

Stamatia V. Destounis, M.D., the lead author of the study and diagnostic radiologist from Elizabeth Wende Breast Care, a huge community based breast imaging center, Rochester, New York, stated that there is huge room for enhancing specificity using ultrasound and elastography could assist in doing that. It could be an easy means of eliminating needle biopsy for something that is possibly benign in nature.

Elastography enhances the specificity of ultrasound by employing conservative ultrasound imaging for measurement of the compressibility and mechanical properties of a lesion. As cancerous tumours have a tendency be firmer as compared to the adjacent normal tissue or cysts, an increasingly compressible lesion appearing on elastography has lesser likelihood of being malignant.

Dr. Destounis explicated that it was possible to conduct elastography at the analogous time as the handheld ultrasound device and viewing the pictures on a split screen, with the 2-D ultrasound imagery on the left and the imagery of the elastography on the right.

During the course of the in-progress study, 179 patients went through breast ultrasound and elastography. The research team acquired 184 elastograms and conducted biopsies on all the firm lesions. From the 134 biopsies, 56 showed cancer. Elastography accurately spotted 98% of the lesions which had malignant discoveries on biopsy, and 82% of lesions emerged to be benign. Elastography was additionally more precise as compared to ultrasound to gauge the size of the lesions.

Dr. Destounis stated that ultrasound could miscalculate the actual size of the lesions, as it solely views the true mass and not the neighbouring variations the mass could be causing.

According to the American Cancer Society that provided breast cancer facts during the year 2009, there would be an approximate 1,92, 370 newly surfaced cases of invasive breast cancer in women in the United States, alongside nearly 62,280 newly evolved cases of ductal carcinoma in situ (DCIS)which is a breast cancer type of an early non-invasive form.

Additionally during the RSNA 2009, Dr. Smitha Putturaya, M.D., F.R.C.R., presented findings derived from a partial, seven-year lasting study done on breast elastography carried out at the Charing Cross Hospital Breast Unit, London, U.K., Dr. Putturaya and associates discovered that on employing elastography as an add-on to regular breast ultrasound securely lowered the number of biopsies of benign lesions and proffers the probability of mapping tumours more accurately.

Monica Morrow, M.D., from the Memorial Sloan-Kettering Cancer Center, New York did the presentation of the study findings at the JAMA media update in Chicago. She stated that the rising worries of mastectomy being used on patients having breast cancer have increased in past twenty years. BCS or breast conservation surgery has been employed by few as a quality measure. In spite of a noticeable rise in BCS, fears continue about the overtreatment with mastectomy on women having breast cancer.

Dr. Marrow and associates carried out a study for ascertaining the reasons why women underwent firstly mastectomy for treating breast cancer and the regularity of mastectomies subsequent to BCS being undertaken. The study comprised of a survey on women in the age bracket of 20-79 years having intraductal or breast cancer stages I and II breast cancer detected in the time periods of June 2005-February 2007. The final study involved 1,984 female participants from different races.

The researchers deciphered that of the patient populace, 75.4% underwent BCS as initial operative treatment; twenty-three percent underwent initial mastectomy; 13.4 percent were given initial mastectomy on the basis of what the surgeon suggested; 8.8% underwent initial mastectomy when the foremost surgeon didn’t suggest one method over the other or suggested BCS; and 8.8% underwent mastectomy subsequent to futile endeavours at BCS.

From the 1,984 patients, 19.1% took a second option regarding operative choices before the treatment. This was prevalent among women that were highly educated and in those that were recommended to go in for mastectomy – about 33.4% versus those recommended to undergo BCS –nearly 15.6% or those that didn’t get a suggestion of one method over the other – about 21.2%.

They additionally detected that 11.9% patients that were given an initial BCS suggestion were given a second opinion for undergoing mastectomy; 12.1% of the patients who visited a second surgeon got a contradictory opinion. Amongst the 1,459 women on whom BCS was carried out, further surgery was needed in 37.9% of patients. Mastectomy was prevalent among patients detected with breast cancer stage II.

The authors wrote that the outcome of the study indicate that majority of the surgeons in two big, different urban areas aptly suggested local treatment choices for patients having breast cancer. Most of the women that got a surgeon advice for initial mastectomy cited a clinical contraindication to breast preservation.

The authors mentioned that their outcomes additionally indicated that patient first choices could don significant role in moulding the outline of surgical treatment for breast cancer. 1/3rds of the patients appeared to opt for mastectomy as the foremost treatment when not offered a precise suggestion for BCS or mastectomy by their surgeon, constituting for nearly one-quarter of total mastectomy usage. Patients could be preferring mastectomy for easing mental strain or for avoiding radiation.

The researchers concluded that the this survey conducted on women with breast cancer illustrates that the cause of present mastectomy rates is due to multiple factors, however BCS is suggested by surgeons and undertaken on most of the patients. Their findings indicate that a collective approach of educating patients and health care experts aiming precise areas could enhance decision making.

In the Aug-09 edition of the Annals of Surgical Oncology, Barth, an associate professor of surgery at Dartmouth Medical School (DMS) and his associates along with Wendy Wells, M.D. – a professor of pathology in DMS suggest employing adjunct radiotherapy on those patients that underwent breast-preservation surgery for controlling borderline malignant and malignant phyllodes tumors.

The follow-ups done on the improvement in 46 women that were given follow-up radiotherapy in thirty diverse organizations in eighteen states, the research group found that none of them showed any development of new-fangled tumors in the spots where the surgeons conducted margin-negative resection.

Amongst approximately five hundred women globally that were detected with the condition annually and underwent solely the surgery, the researchers stated that there was recession of tumors in 24% of patients having borderline malignant tumors and 20% of those women having malignant tumors.

Barth is the section head of general surgery at Dartmouth-Hitchcock Medical Center or DHMC, and Wells is the breast pathologist at DHMC wherein there were thirteen women that were candidates in the study.

These findings are printed in the 17th November 2009 edition of Annals of Internal Medicine.

Scientists at CISNET, the NCI-backed Cancer Intervention and Surveillance Modelling Network, employed independent models for examining twenty screening approaches with varying commencing and halting ages and time intervals. Modelling approximates the lifelong impact (results include advantages and harmful effects) of breast cancer screening mammography. The CISNET is observed to model association known information all through the span of life and involves nationwide information on age-explicit breast cancer occurrence, transience, mammography features and treatment outcomes.

The paper’s lead author Jeanne S. Mandelblatt, M.D., MPH, from Georgetown Lombardi Comprehensive Cancer Center and a CISNET associate stated that it was encouraging to observe all the CISNET modelling sets coming to an analogous conclusion in spite of application of diverse models of these data. Despite the fact that the findings depict a wide-ranging reassessment of existent data, resolutions regarding the optimal screening approach is dependent on individual and public health objectives, resources and forbearance in case of false-positive mammograms, unneeded biopsies and over-analysis.

The CISNET examination reveals that biennial screening has nearly all the advantages (a standard of 81%) of yearly screening with nearly half the number of false-positives. In comparison with no screening, mammography screening done biennially starting from ages 50-69 attains a median lowering in breast cancer mortality of 16.5% over a span of life. In case screening is commenced at age forty vs. Fifty years of age and conducted biennially, there is a median mortality drop of 19.5% (an extra 1 woman per one thousand), but a rise in false-positive outcomes, unneeded biopsies and nervousness.

‘False-positives’ signify mammograms read an anomalous that mostly need additional follow-ups among women that are detected to not have cancer. An unneeded biopsy is the outcome when there is a false-positive mammogram and when the biopsy has normal outcome. ‘Over-diagnosis’ is the cancer detection via screening that would otherwise have continued to be asymptomatic or would have no affect on the woman’s health. As normally it is not likely to ascertain which cancers would show progression, nearly all cancers diagnosed at the time of screening are treated.

Mandelblatt states that the advantages of biennial screening are reliable with what is identified about the breast cancer’s biology. In the major populace of women, majority of the tumors are slow-progressing and this percentage is observed to increase as one ages, hence there is negligible loss in survival advantages all through the populace for annual screening versus biennial screening. In women having belligerent, quick spreading tumors, yearly screening would probably not make a variation in survival. For such women, varied approached could be beneficial and is a significant part of on-going studies.

Mandelblatt explicated that even as the model outcomes verified that mammography helped save lives, there are lesser general advantages from commencing screening prior to fifty years of age as there are few women that developed breast cancer in their younger years, and screening younger-aged women comes along with a huge number of false-positive mammograms that leads to unwarranted strain on women and unwanted biopsies. We require further research for understanding the way to adapt screening to individual risk.

These modelling data characterize an average discovery about the populace of women, hence over-emphasis on the fact that women must discuss with their health care provider about a screening program that is best-suited for them.

During the Molecular Targets and Cancer Therapeutics International Conference, Boston, the researchers from Medical College of Georgia Cancer Center reported that while they are potent obliterators of some breast cancer cells, novel drugs known as histone deacetylase inhibitors (HDAC inhibitors), additionally augment self-assimilation or autophagy, in enduring, mega-strained cells.

Dr. Kapil Bhalla, Director of the MCG Cancer Center stated that for meeting the energy requirements of proliferation and survival, cancer cells commence foraging on their own organelles, so that extant cells turn reliant on this autophagy. He further added that by additionally employing autophagy inhibitors, the scientists intended to obliterate them.

Researchers revealed the powerful HDAC inhibitor panobinostat’s effect on autophagy among human breast cancer cells in culture and in those proliferating in the mammary fat deposits in mice. When the anti-malarial drug chloroquine was added, it inhibited autophagy and there was dramatic rise in breast cancer obliteration rates.

Dr. Bhalla further added that as breast cancer metastasizes, it evolves these means of resistance to fatality. He explicated that this novel method was intended to affect an immune populace.

The essentials of survival and proliferation lay immense strain on cancer cells. Their thrust for both arises from the oncogenes activating and trouncing of tumor suppressor genes that leave cells appearing desperate for means to sustain their marching directions. Analogous to the desperate measures adopted by those victims stuck in a calamity scenario, autophagy turns out to be a survival approach for the highly strained cancer cells.

The cancer cells face immense stress when the available reserve of blood and nutrients get swiftly exhausted, that encourages novel blood vessel creation and burning up of extraordinary quantities of fuel. Variations in gene copy numbers produce a disparity in gene products or proteins summing up to the stress faced by the cancer cells, that are commencing to produce reprehensively folded and working proteins.

Dr. Bhalla added that there is a revving up of protein deprivation and cells additionally commence producing further heat shock proteins that are believed to aid appropriately to fold proteins and safeguard from cell fatality, a cause and outcome for stress- something that Dr. Bhalla revealed about a decade back. He doubted then the association he presently has discovered: encouraging autophagy is one approach that the heat shock proteins conduct their defensive operation.

HDAC inhibitors come into action wherein they elicit acetylation or an amendment in the key heat shock protein, hsp70 that further encourages autophagy. Essentially, HDAC inhibitors endorse acetylated hsp70 that encourages autophagy on which a highly stressed cancer cell is depending on.

He further noted that chloroquine – an identified anti-malarial and autophagy inhibitor, is already being coalesced with chemotherapy and radiation in few of the cancer trials. However, due to its major side effects, novel, more bearable autophagy inhibitors are needed to be developed that could be merged with the presently obtainable cancer-combatant agents, like panobinostat, to achieve enhanced remedial breast cancer treatments.